Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus ZORVOLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus ZORVOLEX.
COXANTO vs ZORVOLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
ZORVOLEX (diclofenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever.
1 g intravenous every 6 hours.
50 mg orally every 8 hours or 100 mg orally every 12 hours; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Terminal elimination half-life of the dual-release formulation is approximately 6-7 hours. Clinical context: Allows twice-daily dosing for sustained analgesic effect.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal excretion of metabolites and conjugates accounts for approximately 50% of the dose, with biliary/fecal elimination of the remainder. Less than 5% is excreted unchanged in urine.
Category C
Category C
NSAID
NSAID